Refractory Chronic Lymphocytic Leukemia Clinical Trials

158 clinical trials for Refractory Chronic Lymphocytic Leukemia across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia — RECRUITING · PHASE2
• Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies — RECRUITING · PHASE1
• Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial — RECRUITING · PHASE2
• Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — RECRUITING · PHASE2
• B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies — RECRUITING · PHASE1
• Q702 for the Treatment of Patients With Hematologic Malignancies — RECRUITING · PHASE1
• Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia — RECRUITING
• Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia — SUSPENDED · PHASE1
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies — TERMINATED · PHASE1
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE2
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant — COMPLETED · PHASE3
• Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL — ACTIVE_NOT_RECRUITING · PHASE2
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study — TERMINATED · PHASE2
• Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL — COMPLETED · PHASE2
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies — TERMINATED · PHASE1
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma — COMPLETED · PHASE1
• Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation — WITHDRAWN · PHASE1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — COMPLETED · PHASE1
• Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas — TERMINATED · PHASE2
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation — COMPLETED · PHASE2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies — COMPLETED · PHASE1
• A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome — TERMINATED · PHASE1
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant — COMPLETED · PHASE2
• Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor — WITHDRAWN · PHASE1
• Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer — TERMINATED · PHASE2
• Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma — WITHDRAWN · PHASE1
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy — COMPLETED · PHASE1
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — TERMINATED · PHASE2
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — COMPLETED · PHASE1
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies — TERMINATED · PHASE1
• Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia — COMPLETED · PHASE1
• Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL — WITHDRAWN · PHASE1
• Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL — COMPLETED · PHASE2
• CD19-Specific T Cells Post AlloSCT — TERMINATED · PHASE1

Refine this search